RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up

Leukemia
R A PaduaR West

Abstract

The molecular mechanisms underlying the development and evolution of myelodysplastic syndrome (MDS) are largely unknown. The increasing number of blast cells in the bone marrow correlate with poor prognosis and risk of developing acute leukemia. Such progression is frequently associated with increasing chromosomal abnormalities and genetic mutations. A cohort of 75 MDS patients were investigated for RAS, FMS and p53 mutations, and these molecular findings were related to cytogenetics, clinical status, transformation to acute leukemia, prognostic scores and survival. A mutation incidence of 57% (43/75) was found, with 48% (36/75) RAS mutations, 12% (9/75) FMS mutations and 8% (4/50) p53 mutations. The mutation status for RAS and FMS was related to MDS subgroup, increasing with poor-risk disease. The highest incidence was in the chronic myelomonocytic leukemia (CMML) subgroup. The most frequent RAS mutations were of codon 12 and a predominance of FMS codon 969 mutations was observed. A statistically significant increased frequency of transformation to AML was observed in MDS patients harboring RAS or FMS mutations (P < 0.02). Patients with oncogene mutations had a significantly poorer survival compared with those without mutation...Continue Reading

Associated Clinical Trials

Nov 11, 2008·Marc Gautier, Marc Gautier

Citations

Oct 3, 2003·Current Oncology Reports·Soheil MeshinchiRobert J Arceci
Apr 21, 2010·Pathology Oncology Research : POR·Jelena StojsicBiljana Jekic
Oct 21, 2004·Best Practice & Research. Clinical Haematology·Steven D Gore
Jun 7, 2005·Cancer Letters·Anna D Panani, Charis Roussos
Feb 6, 2004·Seminars in Cancer Biology·Alison M JohnRose Ann Padua
Jan 16, 2003·Leukemia Research·David P Steensma, Ayalew Tefferi
May 5, 2001·Pharmacology & Therapeutics·C R Weinstein-OppenheimerJ A McCubrey
Jan 22, 2004·Cancer Genetics and Cytogenetics·Jeanna WelbornPaula Walling
Dec 20, 2002·Blood Reviews·Derek L StirewaltJerald P Radich
Jun 24, 2003·Blood Reviews·Jeffrey E Lancet, Judith E Karp
Jan 18, 2008·Leukemia·J Pedersen-BjergaardD H Christiansen
Jun 10, 2000·British Journal of Haematology·S D MundleA Raza
May 25, 2002·British Journal of Haematology·Rajeev GuptaBarbara J Bain
Jul 1, 2011·The New England Journal of Medicine·Rafael BejarBenjamin L Ebert
May 13, 2009·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey W TynerBrian J Druker
May 17, 2000·Journal of Hematotherapy & Stem Cell Research·K AllampallamA Raza
Feb 25, 2000·Current Opinion in Oncology·R Dansey
Jan 27, 2007·Current Opinion in Hematology·Torsten HaferlachSusanne Schnittger
Dec 21, 2000·British Journal of Haematology·R A Padua, R R West
May 2, 2006·Molecular and Cellular Biology·Nader OmidvarRichard L Darley
Jun 7, 2008·Hematology·Michela PalmisanoGiovanni Martinelli
Aug 12, 2009·Blood·Olivier KosmiderUNKNOWN Groupe Francophone des Myélodysplasies
Oct 16, 2004·International Journal of Hematology·Gurveen SaberwalSuneel D Mundle
Mar 13, 2010·Future Oncology·Florian Nolte, Wolf-K Hofmann
Feb 11, 2014·Best Practice & Research. Clinical Haematology·Raphael ItzyksonEric Solary
Jul 12, 2003·Leukemia & Lymphoma·Shigeo HoriikeMasafumi Taniwaki
Nov 19, 2010·Expert Review of Hematology·Judith NeukirchenUlrich Germing
Mar 23, 2011·Expert Opinion on Drug Safety·Prerna Mewawalla, Constantin A Dasanu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.